Core Insights - Pacira BioSciences announced findings from two real-world studies demonstrating the economic benefits of EXPAREL in total knee arthroplasty (TKA) and spinal fusion, showing lower total costs of care compared to traditional analgesics [1][2] Study Findings - The studies included propensity score-matched cohorts evaluating outcomes on surgery day and through 30 days of follow-up in commercial and Medicare Advantage populations, revealing lower total costs and reduced healthcare resource utilization with EXPAREL [2] - In the spinal fusion study, the reductions in costs were primarily attributed to a shorter length of hospital stay for patients treated with EXPAREL [2] Specific Results from TKA Study - In the TKA study, EXPAREL was associated with significantly lower total costs compared to ropivacaine, with reductions of $409 in the commercial cohort and $1,359 in the Medicare Advantage cohort, both with P<0.001 [3] - The index procedure costs were also lower for EXPAREL, with reductions of $328 and $781 for commercial and Medicare Advantage cohorts respectively, both with P<0.0001 [3] - Additional findings included reduced home health utilization and lower inpatient admissions in the commercial population, with P<0.05 for all [3] Specific Results from Spinal Fusion Study - In the spinal fusion study, patients treated with EXPAREL had significantly lower mean total costs of $5,993.17 compared to non-LB analgesia, with P<0.05 [4] - The reduction in total medical costs was $6,001.19, also with P<0.05, and there were decreases in outpatient costs [4] - Patients treated with EXPAREL experienced a shorter length of stay by 1.83 days, with P<0.0001, and no differences in emergency department visits or inpatient readmissions [5] Company Commitment - Pacira is dedicated to advancing the economic understanding of postsurgical pain management through real-world evidence, emphasizing the value of non-opioid approaches like EXPAREL [3] - The findings support the role of EXPAREL in multimodal pain management strategies, aiming to improve patient outcomes and reduce economic barriers to access [3] Upcoming Presentations - Pacira will present these findings at the Orthopaedic Research Society (ORS) 2026 Annual Meeting, highlighting the economic advantages of EXPAREL in orthopedic procedures [1][3]

Company Overview - Pacira BioSciences, Inc. is a leader in delivering innovative, non-opioid pain therapies aimed at transforming patient lives [2] - The company has three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera® [2] - EXPAREL® is a long-acting local analgesic approved for various postsurgical pain management techniques [2] - ZILRETTA® is an extended-release injectable for managing osteoarthritis knee pain [2] - iovera® is a handheld device providing immediate, long-acting, drug-free pain control through controlled cold temperature application [2] - Pacira is advancing a pipeline of clinical-stage assets, including PCRX-201, a gene therapy for osteoarthritis of the knee currently in Phase 2 clinical development [2] Upcoming Events - Pacira will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 [1] - The event will take place at 2:30 PM ET in Miami, with live audio accessible on the company's website [1] - A replay of the webcast will be available for two weeks following the event [1]

Core Insights - Pacira BioSciences presented real-world evidence demonstrating the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for osteoarthritis patients at the AAOS 2026 Annual Meeting [1][2] Group 1: EXPAREL Findings - The first study indicated that patients receiving EXPAREL showed significant improvements in pain, opioid use, function, and length of stay after total knee arthroplasty compared to those receiving conventional bupivacaine and ropivacaine [1][3] - Patients treated with EXPAREL reported lower average pain scores (3.9 vs 4.9) and worst pain scores (5.9 vs 7.1) in the first five days post-surgery, with statistical significance (P<0.001) [3] - Patients receiving EXPAREL were discharged earlier (15.0 hours) compared to those receiving conventional local anesthetics (20.6 hours) [3] Group 2: ioveraº Findings - The second study showed that cryoneurolysis treatment with ioveraº resulted in long-term pain and functional improvements for up to 12 months, significantly exceeding the typical 4-6 months of relief from alternative intra-articular agents [1][3] - Data from 129 patients indicated that cryoneurolysis was associated with long-term reductions in pain and improved function (P<0.01) [3] Group 3: Innovations in Genicular Outcomes Registry (IGOR) - IGOR is a first-of-its-kind multicenter, prospective, longitudinal observational registry aimed at providing real-world evidence and insights into the patient journey for osteoarthritis treatment [2][11] - The registry collects comprehensive data on patient characteristics, clinical outcomes, and economic impacts, contributing to evidence-based preoperative pain management strategies [2][11] Group 4: Company Overview - Pacira BioSciences focuses on innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and ioveraº [4] - The company is advancing a pipeline of clinical-stage assets, including PCRX-201, a novel gene therapy for knee osteoarthritis currently in Phase 2 clinical development [4]

Core Viewpoint - Pacira BioSciences, Inc. is set to report its fourth quarter and full year financial results for 2025 on February 26, 2026, after U.S. market close, followed by a live conference call and webcast [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL®: a long-acting local analgesic approved for various postsurgical pain management techniques [3] - ZILRETTA®: an extended-release injectable for managing osteoarthritis knee pain [3] - iovera®: a handheld device providing immediate, long-acting, drug-free pain control through cold temperature application [3] - Pacira is advancing a pipeline of clinical-stage assets for musculoskeletal pain, with its leading candidate, PCRX-201, in Phase 2 clinical development for knee osteoarthritis [3]

Core Insights - Pacira BioSciences, Inc. is focused on delivering innovative, non-opioid pain therapies and has highlighted new survey findings from the Voices for Non-Opioid Choices coalition regarding the impact of the Non-Opioids Prevent Addiction (NOPAIN) Act [1][2] Group 1: NOPAIN Act Impact - The NOPAIN Act, effective January 1, 2025, aims to prevent opioid addiction by increasing access to non-opioid pain management options for Medicare beneficiaries undergoing surgery [3] - A national survey of nearly 750 healthcare facilities showed that 85% of facility representatives were aware of the NOPAIN Act, and 52% had taken steps to increase the use of qualifying non-opioid options [7] - Over 80% of respondents reported a decrease in opioid prescribing immediately after surgery (83%) and at discharge (88%) due to the legislation [7] Group 2: Company Position and Products - Pacira's CEO emphasized that the NOPAIN Act is a significant step forward for expanding access to non-opioid pain management options, particularly for Medicare patients [3] - Pacira offers three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera®, with a pipeline of clinical-stage assets including PCRX-201, a gene therapy for osteoarthritis of the knee [5] - The company is committed to transforming patient lives through innovative pain therapies and is actively tracking the impact of the NOPAIN Act on opioid reliance [3][5]

Core Insights - Pacira BioSciences, Inc. has appointed Dr. Samit Hirawat to its Board of Directors, expanding the board to 10 members [1][2] Company Overview - Pacira is focused on delivering innovative, non-opioid pain therapies aimed at transforming patient lives [4] - The company has three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera® [4] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications [4] - ZILRETTA is an extended-release injectable for managing osteoarthritis knee pain [4] - iovera® is a handheld device providing immediate, long-acting, drug-free pain control [4] - Pacira is advancing a pipeline of clinical-stage assets, including PCRX-201, a gene therapy in Phase 2 development for knee osteoarthritis [4] Leadership and Expertise - Dr. Hirawat brings over 25 years of clinical development and industry expertise, previously serving as Chief Medical Officer at Bristol Myers Squibb [2][3] - His experience includes overseeing global drug development and advancing transformative therapies across various therapeutic areas [2] - Dr. Hirawat has a strong academic background with over 150 peer-reviewed publications [3]

Core Insights - Pacira BioSciences has partnered with LG Chem to expand access to opioid-sparing postsurgical pain control in select Asia-Pacific markets through the exclusive commercialization of EXPAREL [1][2] Company Overview - Pacira BioSciences is focused on delivering innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera® [3] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management techniques [3] - ZILRETTA is an extended-release injectable for osteoarthritis knee pain management [3] - Iovera® is a handheld device providing immediate, long-acting, drug-free pain control [3] - The company is advancing a pipeline of clinical-stage assets, including PCRX-201, a gene therapy for osteoarthritis of the knee in Phase 2 development [3] Partnership Details - LG Chem will have exclusive rights to commercialize EXPAREL in the designated territories, leveraging its experience in orthopedic pain management [2] - Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future sales by LG Chem [2] - LG Chem is responsible for obtaining regulatory approvals in the licensed territories, with plans to file for marketing authorizations in South Korea and Thailand within six months [2]

Core Insights - Pacira BioSciences, Inc. is committed to delivering innovative, non-opioid pain therapies to transform patients' lives [1][2] - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 AM PST [1] Company Overview - Pacira has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic approved for various postsurgical pain management techniques [2] - ZILRETTA, an extended-release injectable for osteoarthritis knee pain management [2] - iovera®, a handheld device providing immediate, long-acting, drug-free pain control [2] - The company is advancing a pipeline of clinical-stage assets, including PCRX-201, a novel gene therapy in Phase 2 development for knee osteoarthritis [2]

Core Insights - The study published in Pain Physician shows that iovera° cryoneurolysis significantly improves functional outcomes for chronic low back pain patients compared to radiofrequency ablation (RFA) [1][6] - Patients treated with iovera° experienced lower pain scores and improved functional disability over a 12-month period [8] Study Findings - The pilot study involved 30 patients with facet-mediated chronic low back pain, comparing iovera° to RFA [4] - At 180 days, pain scores for iovera° patients were 3.1 compared to 5.4 for RFA patients (p=0.01) [8] - At 360 days, pain scores for iovera° patients were 3.0 compared to 6.1 for RFA patients (p=0.01) [8] - Functional disability, measured by the Oswestry Disability Index (ODI), showed iovera° patients scoring 10.1 at 360 days versus 20.6 for RFA patients (p=0.002) [8] - Fewer iovera° patients required additional spine injections after 180 days, with 45.5% needing further treatment compared to 75% of RFA patients [8] - No treatment-related adverse events were reported in either group during the 12-month follow-up [8] Treatment Mechanism - The iovera° system utilizes cryoneurolysis, applying focused cold therapy to targeted nerves to interrupt pain signal transmission [2][8] - Pain relief is typically immediate and can last up to 90 days as the nerve regenerates [2][9] Industry Context - Chronic low back pain is a leading cause of disability in the U.S. and contributes significantly to opioid use [3] - The need for alternative, tissue-sparing approaches like cryoneurolysis is underscored by the potential tissue damage associated with RFA [3] - The FDA recently cleared a new SmartTip for iovera° to allow deeper nerve access for lumbar applications, supporting ongoing clinical evidence expansion [6]

Core Insights - Pacira BioSciences has announced an exclusive worldwide license and collaboration agreement with AmacaThera for the development of AMT-143, a novel long-acting formulation of the non-opioid analgesic ropivacaine aimed at postsurgical pain control [1][2] Company Strategy - The addition of AMT-143 to the pipeline aligns with Pacira's 5x30 growth strategy, focusing on clinical stage, derisked opportunities that complement existing pain management offerings [2] - The company aims to enhance its leadership in opioid-sparing pain management through this new asset, which is expected to improve patient outcomes and expand treatment options [2] Financial Terms of the Agreement - Under the agreement, Pacira will fund the clinical development up to commercial launch, with AmacaThera receiving an upfront payment of $5 million, along with potential future milestone payments and a tiered royalty on net sales [3] Product Details - AMT-143 is designed for postsurgical pain control and demonstrated sustained release of ropivacaine for up to 14 days in a Phase 1 study [4] - The product utilizes AmacaThera's hydrogel-based drug delivery platform, which allows for slow release while minimizing systemic side effects [5] Current Product Portfolio - Pacira currently offers three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera, which target various pain management needs [6]